These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 11007248)

  • 1. Algorithm for the treatment of Crohn's disease: incorporation of emerging therapies.
    Souney PF
    Am J Gastroenterol; 2000 Sep; 95(9):2381-3. PubMed ID: 11007248
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Crohn's disease at the turn of the century.
    Bickston SJ; Cominelli F
    N Engl J Med; 1998 Aug; 339(6):401-2. PubMed ID: 9691110
    [No Abstract]   [Full Text] [Related]  

  • 3. [Drug therapy of inflammatory bowel diseases].
    Silvennoinen J; Niemelä S
    Duodecim; 1999; 115(20):2233-8. PubMed ID: 11973927
    [No Abstract]   [Full Text] [Related]  

  • 4. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease.
    Bauditz J; Lochs H; Schreiber S
    N Engl J Med; 1998 Jan; 338(5):334. PubMed ID: 9446035
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of vulval Crohn's disease with infliximab.
    Preston PW; Hudson N; Lewis FM
    Clin Exp Dermatol; 2006 May; 31(3):378-80. PubMed ID: 16681581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [From research to clinic: The case of Crohn's disease and Tumor Necrosis Factor].
    Pellicano R
    Minerva Gastroenterol Dietol; 2000 Jun; 46(2):131-8. PubMed ID: 19320082
    [No Abstract]   [Full Text] [Related]  

  • 7. Longstanding Crohn's vulvitis successfully treated with combined anti-TNFα antibody and azathioprine.
    Macdonagh E; Pugh S; Fox R
    J Obstet Gynaecol; 2013 Jul; 33(5):530. PubMed ID: 23815219
    [No Abstract]   [Full Text] [Related]  

  • 8. [Biological drugs in inflammatory bowel disease. Valuable supplement--but only when conventional therapy is not sufficient].
    Hellström PM; Schmidt D; Karlén P
    Lakartidningen; 2007 Oct 10-16; 104(41):2973-6. PubMed ID: 17977308
    [No Abstract]   [Full Text] [Related]  

  • 9. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease.
    González Carro P; Pérez Roldán F; Roncero García Escribano O; Lafuente R; Legaz Huidobro ML; Amigo Echenagusía A
    J Clin Apher; 2006 Dec; 21(4):249-51. PubMed ID: 16607627
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug therapy of Crohn disease].
    Niemelä S
    Duodecim; 2001; 117(8):807-14. PubMed ID: 12116446
    [No Abstract]   [Full Text] [Related]  

  • 11. Aminosalicylates for active disease and in the maintenance of remission in Crohn's disease.
    Feagan BG
    Eur J Surg; 1998 Dec; 164(12):903-9. PubMed ID: 10029385
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of fistulizing Crohn's disease.
    Judge TA; Lichtenstein GR
    Gastroenterol Clin North Am; 2004 Jun; 33(2):421-54, xi-xii. PubMed ID: 15177547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prediction of response to infliximab in Crohn's disease.
    Chaudhary R; Ghosh S
    Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
    [No Abstract]   [Full Text] [Related]  

  • 14. Managing complicated Crohn's disease in children and adolescents.
    Homan M; Baldassano RN; Mamula P
    Nat Clin Pract Gastroenterol Hepatol; 2005 Dec; 2(12):572-9. PubMed ID: 16327836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab: new indication. Severe Crohn's disease: a second TNF alpha antagonist, subcutaneous administration.
    Prescrire Int; 2008 Aug; 17(96):137. PubMed ID: 19480092
    [No Abstract]   [Full Text] [Related]  

  • 16. Maintenance of medically induced remission of Crohn's disease.
    Gonvers JJ; Juillerat P; Mottet C; Pittet V; Felley C; Vader JP; Michetti P; Froehlich F
    Digestion; 2007; 76(2):116-29. PubMed ID: 18239403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [What can be expected from biological therapies for Crohn's disease?].
    Lemann M
    Gastroenterol Clin Biol; 2001 Nov; 25(11):945-7. PubMed ID: 11845043
    [No Abstract]   [Full Text] [Related]  

  • 18. Medical therapy for refractory pediatric Crohn's disease.
    Faubion WA; Bousvaros A
    Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1199-213. PubMed ID: 16872913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tumour necrosis factor-alpha therapies in Crohn's disease.
    Sprakes MB; Hamlin PJ
    Br J Hosp Med (Lond); 2009 Nov; 70(11):644-7. PubMed ID: 20081592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.